PV Bulletin

Submission of Post Approval Changes Applications of Registration Certificate and Import Licence of Human Vaccines and Anti-sera through SUGAM Portal

CDSCO mandates online applications for post-approval changes for vaccines in India.

Primary source: BA/BE

PV Impact Brief

Urgency: HighConfidence: high

What changed

CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.

Why it matters

This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.

Action needed

MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Country ComplianceLabeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Circular
Policy status
effective
Publication date
2026-06-24
Policy change
CDSCO mandated the use of the SUGAM online portal for submitting applications related to post-approval changes for registration certificates and import licenses of human vaccines and anti-sera.

Key changes

Transition from manual/offline submissions to mandatory online filings through the SUGAM portal for all vaccine-related post-approval changes.

Affected workflows

Country ComplianceLabeling

Responsible groups

Regulatory AffairsPV Operations

PV impact

Safety-related variations and updates to product information for vaccines in India must now be processed through the SUGAM portal, requiring MAHs to update their submission procedures.

View regulator source

Source document details

Exact policy details

Submission of Post Approval Changes Applications
Effective from 2026-Jun-24
Applies to: Human Vaccines and Anti-sera
Submission of Post Approval Changes Applications of Registration Certificate and Import Licence of Human Vaccines and Anti-sera through SUGAM Portal · p. 1 · High · Source

Extracted documents

Unable to extract linked source document: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp

Evidence and confidence

Confidence: highSource updated: Jun 26, 2026

Full briefing

Practical implication

MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

The Central Drugs Standard Control Organisation (CDSCO) has implemented a new requirement mandating that all applications related to post-approval changes for registration certificates and import licenses of human vaccines and anti-sera be submitted exclusively through the SUGAM online portal. This shift from manual to online submissions includes safety-related updates and variations, necessitating that Marketing Authorization Holders (MAHs) revise their submission procedures accordingly.

What changed: CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.

Why it matters: This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.

Practical implication: MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Reporting Requirement#policy-change#firecrawl-policy-agent#Effective#Circular#Central Drugs Standard Control Organisation (CDSCO)

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward